Emerging Data for HER2 ADCs in Ovarian Cancer : vimarsana.co

Ritu Salani, MD, presents an outline of the treatment landscape for ovarian cancer and underscores encouraging data from the DESTINY-PanTumor02 study, showcasing promising results in this treatment setting.

Related Keywords

, Updates Across Solid Tumors , Ther2 , Gynecologic Oncology , Adcs , Solid Tumors , Biomarkers , Pan Tumor Biomarker , Endometrial Cancer , Ovarian Cancer ,